2篇
您的检索式：作者名="Monika Lessl"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Collaboration for success:the value of strategic collaborations for precision medicine and biomarker discovery显示文摘Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point of time.Biomarkers(BM)are vital for the identification of patients who would benefit the most from individualized treatment.In addition,they help to enable the prediction of prognosis,the detection of early therapeutic and adverse effects,and may serve as surrogate endpoints in clinical trials.BM are becoming essential tools to increase productivity in drug discovery and impressively enhance the way medicine is practiced.However,the identification,sufficient validation and implementation of such BM are challenging.This process requires expertise from different areas and high resource investments.Collaborations of different partners may be helpful to overcome these challenges.In the past decade,collaborations between diagnostics and pharmaceutical companies as well as industrial–academic collaborations have been increasingly pursued.Moreover,public funding may offer support and open new opportunities to form such consortia.Herein we give an overview of the different types of collaborations,their opportunities and challenges,and describe experiences in forming strategic partnerships with other companies. | Lilla Landeck Monika Lessl Joachim Reischl Andreas Busch Patricia Carrigan Matthias Gottwald Petra Reinke Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，1： | 3 |
| 2 | The role of open innovation in biomarker discovery显示文摘Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close collaboration between different partners seems to be a key success factor. While the importance of partnerships and larger, well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well understood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for biomarkers’, is still in its infancy. Crowd sourcing comprises of a — usually via internet — request for problem solution to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad community with different expertise, this approach is particularly promising for BM development. In this article we describe the first examples of open-innovation models, such as the ‘grants for targets’(G4T) and biomarkers initiative ‘InnoCentive’(innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the future. | Lilla Landeck Monika Lessl Andreas Busch Matthias Gottwald Khusru Asadullah | 2016 | Advances in Precision Medicine2016，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员